Discovery - University of Dundee - Online Publications

Library & Learning Centre

Lipid-Modifying Therapies and Risk of Pancreatitis

Standard

Lipid-Modifying Therapies and Risk of Pancreatitis : a Meta-analysis. / Preiss, David; Tikkanen, Matti J.; Welsh, Paul; Ford, Ian; Lovato, Laura C.; Elam, Marshall B.; LaRosa, John C.; DeMicco, David A.; Colhoun, Helen M.; Goldenberg, Ilan; Murphy, Michael J.; MacDonald, Thomas M.; Pedersen, Terje R.; Keech, Anthony C.; Ridker, Paul M.; Kjekshus, John; Sattar, Naveed; McMurray, John J. V.

In: JAMA: the Journal of the American Medical Association, Vol. 308, No. 8, 2012, p. 804-811.

Research output: Contribution to journalArticle

Harvard

Preiss, D, Tikkanen, MJ, Welsh, P, Ford, I, Lovato, LC, Elam, MB, LaRosa, JC, DeMicco, DA, Colhoun, HM, Goldenberg, I, Murphy, MJ, MacDonald, TM, Pedersen, TR, Keech, AC, Ridker, PM, Kjekshus, J, Sattar, N & McMurray, JJV 2012, 'Lipid-Modifying Therapies and Risk of Pancreatitis: a Meta-analysis' JAMA: the Journal of the American Medical Association, vol 308, no. 8, pp. 804-811., 10.1001/jama.2012.8439

APA

Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., ... McMurray, J. J. V. (2012). Lipid-Modifying Therapies and Risk of Pancreatitis: a Meta-analysis. JAMA: the Journal of the American Medical Association, 308(8), 804-811. 10.1001/jama.2012.8439

Vancouver

Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB et al. Lipid-Modifying Therapies and Risk of Pancreatitis: a Meta-analysis. JAMA: the Journal of the American Medical Association. 2012;308(8):804-811. Available from: 10.1001/jama.2012.8439

Author

Preiss, David; Tikkanen, Matti J.; Welsh, Paul; Ford, Ian; Lovato, Laura C.; Elam, Marshall B.; LaRosa, John C.; DeMicco, David A.; Colhoun, Helen M.; Goldenberg, Ilan; Murphy, Michael J.; MacDonald, Thomas M.; Pedersen, Terje R.; Keech, Anthony C.; Ridker, Paul M.; Kjekshus, John; Sattar, Naveed; McMurray, John J. V. / Lipid-Modifying Therapies and Risk of Pancreatitis : a Meta-analysis.

In: JAMA: the Journal of the American Medical Association, Vol. 308, No. 8, 2012, p. 804-811.

Research output: Contribution to journalArticle

Bibtex - Download

@article{f8f0bbddcdde402ca62c5fd60c277a46,
title = "Lipid-Modifying Therapies and Risk of Pancreatitis: a Meta-analysis",
author = "David Preiss and Tikkanen, {Matti J.} and Paul Welsh and Ian Ford and Lovato, {Laura C.} and Elam, {Marshall B.} and LaRosa, {John C.} and DeMicco, {David A.} and Colhoun, {Helen M.} and Ilan Goldenberg and Murphy, {Michael J.} and MacDonald, {Thomas M.} and Pedersen, {Terje R.} and Keech, {Anthony C.} and Ridker, {Paul M.} and John Kjekshus and Naveed Sattar and McMurray, {John J. V.}",
note = "Copyright 2012 Elsevier B.V., All rights reserved.",
year = "2012",
doi = "10.1001/jama.2012.8439",
volume = "308",
number = "8",
pages = "804--811",
journal = "JAMA: the Journal of the American Medical Association",
issn = "0098-7484",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Lipid-Modifying Therapies and Risk of Pancreatitis

T2 - a Meta-analysis

A1 - Preiss,David

A1 - Tikkanen,Matti J.

A1 - Welsh,Paul

A1 - Ford,Ian

A1 - Lovato,Laura C.

A1 - Elam,Marshall B.

A1 - LaRosa,John C.

A1 - DeMicco,David A.

A1 - Colhoun,Helen M.

A1 - Goldenberg,Ilan

A1 - Murphy,Michael J.

A1 - MacDonald,Thomas M.

A1 - Pedersen,Terje R.

A1 - Keech,Anthony C.

A1 - Ridker,Paul M.

A1 - Kjekshus,John

A1 - Sattar,Naveed

A1 - McMurray,John J. V.

AU - Preiss,David

AU - Tikkanen,Matti J.

AU - Welsh,Paul

AU - Ford,Ian

AU - Lovato,Laura C.

AU - Elam,Marshall B.

AU - LaRosa,John C.

AU - DeMicco,David A.

AU - Colhoun,Helen M.

AU - Goldenberg,Ilan

AU - Murphy,Michael J.

AU - MacDonald,Thomas M.

AU - Pedersen,Terje R.

AU - Keech,Anthony C.

AU - Ridker,Paul M.

AU - Kjekshus,John

AU - Sattar,Naveed

AU - McMurray,John J. V.

PY - 2012

Y1 - 2012

N2 - <p>Context Statin therapy has been associated with pancreatitis in observational studies. Although lipid guidelines recommend fibrate therapy to reduce pancreatitis risk in persons with hypertriglyceridemia, fibrates may lead to the development of gallstones, a risk factor for pancreatitis.</p><p>Objective To investigate associations between statin or fibrate therapy and incident pancreatitis in large randomized trials.</p><p>Data Sources Relevant trials were identified in literature searches of MEDLINE, EMBASE, and Web of Science (January 1, 1994, for statin trials and January 1, 1972, for fibrate trials, through June 9, 2012). Published pancreatitis data were tabulated where available (6 trials). Unpublished data were obtained from investigators (22 trials).</p><p>Study Selection We included randomized controlled cardiovascular end-point trials investigating effects of statin therapy or fibrate therapy. Studies with more than 1000 participants followed up for more than 1 year were included.</p><p>Data Extraction Trial-specific data described numbers of participants developing pancreatitis and change in triglyceride levels at 1 year. Trial-specific risk ratios (RRs) were calculated and combined using random-effects model meta-analysis. Between-study heterogeneity was assessed using the I-2 statistic.</p><p>Results In 16 placebo-and standard care-controlled statin trials with 113 800 participants conducted over a weighted mean follow-up of 4.1 (SD, 1.5) years, 309 participants developed pancreatitis (134 assigned to statin, 175 assigned to control) (RR, 0.77 [95% CI, 0.62-0.97; P=.03; I-2=0%]). In 5 dose-comparison statin trials with 39 614 participants conducted over 4.8 (SD, 1.7) years, 156 participants developed pancreatitis (70 assigned to intensive dose, 86 assigned to moderate dose) (RR, 0.82 [95% CI, 0.59-1.12; P=.21; I-2=0%]). Combined results for all 21 statin trials provided RR 0.79 (95% CI, 0.65-0.95; P=.01; I-2=0%). In 7 fibrate trials with 40 162 participants conducted over 5.3 (SD, 0.5) years, 144 participants developed pancreatitis (84 assigned to fibrate therapy, 60 assigned to placebo) (RR, 1.39 [95% CI, 1.00-1.95; P=.053; I-2=0%]).</p><p>Conclusion In a pooled analysis of randomized trial data, use of statin therapy was associated with a lower risk of pancreatitis in patients with normal or mildly elevated triglyceride levels. JAMA. 2012;308(8):804-811 www.jama.com</p>

AB - <p>Context Statin therapy has been associated with pancreatitis in observational studies. Although lipid guidelines recommend fibrate therapy to reduce pancreatitis risk in persons with hypertriglyceridemia, fibrates may lead to the development of gallstones, a risk factor for pancreatitis.</p><p>Objective To investigate associations between statin or fibrate therapy and incident pancreatitis in large randomized trials.</p><p>Data Sources Relevant trials were identified in literature searches of MEDLINE, EMBASE, and Web of Science (January 1, 1994, for statin trials and January 1, 1972, for fibrate trials, through June 9, 2012). Published pancreatitis data were tabulated where available (6 trials). Unpublished data were obtained from investigators (22 trials).</p><p>Study Selection We included randomized controlled cardiovascular end-point trials investigating effects of statin therapy or fibrate therapy. Studies with more than 1000 participants followed up for more than 1 year were included.</p><p>Data Extraction Trial-specific data described numbers of participants developing pancreatitis and change in triglyceride levels at 1 year. Trial-specific risk ratios (RRs) were calculated and combined using random-effects model meta-analysis. Between-study heterogeneity was assessed using the I-2 statistic.</p><p>Results In 16 placebo-and standard care-controlled statin trials with 113 800 participants conducted over a weighted mean follow-up of 4.1 (SD, 1.5) years, 309 participants developed pancreatitis (134 assigned to statin, 175 assigned to control) (RR, 0.77 [95% CI, 0.62-0.97; P=.03; I-2=0%]). In 5 dose-comparison statin trials with 39 614 participants conducted over 4.8 (SD, 1.7) years, 156 participants developed pancreatitis (70 assigned to intensive dose, 86 assigned to moderate dose) (RR, 0.82 [95% CI, 0.59-1.12; P=.21; I-2=0%]). Combined results for all 21 statin trials provided RR 0.79 (95% CI, 0.65-0.95; P=.01; I-2=0%). In 7 fibrate trials with 40 162 participants conducted over 5.3 (SD, 0.5) years, 144 participants developed pancreatitis (84 assigned to fibrate therapy, 60 assigned to placebo) (RR, 1.39 [95% CI, 1.00-1.95; P=.053; I-2=0%]).</p><p>Conclusion In a pooled analysis of randomized trial data, use of statin therapy was associated with a lower risk of pancreatitis in patients with normal or mildly elevated triglyceride levels. JAMA. 2012;308(8):804-811 www.jama.com</p>

UR - http://www.scopus.com/inward/record.url?scp=84865338549&partnerID=8YFLogxK

U2 - 10.1001/jama.2012.8439

DO - 10.1001/jama.2012.8439

M1 - Article

JO - JAMA: the Journal of the American Medical Association

JF - JAMA: the Journal of the American Medical Association

SN - 0098-7484

IS - 8

VL - 308

SP - 804

EP - 811

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy